Review of influenza A and secondary bacterial infections identifies critical knowledge gaps

Photo by National Institute of Allergy and Infectious Diseases / Unsplash

Frontiers in Medicine Published May 25, 2026 Medically reviewed May 25, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider that this review highlights critical knowledge gaps in influenza and secondary bacterial infections.

This is a narrative review that examines influenza A virus infection, secondary bacterial infection, and nosocomial infection. The authors did not report a specific study population, sample size, intervention, comparator, or primary outcome. The review's scope is to synthesize existing evidence on these conditions.

The authors did not report pooled effect sizes or specific numerical findings from primary studies. The main synthesized argument is that critical knowledge gaps exist in the understanding of these infections. No specific practice recommendations are provided.

The authors explicitly note critical knowledge gaps as a limitation. The review does not report on safety, adverse events, or practice relevance. The conclusions are qualitative and do not support causal statements.

Given the absence of specific data, the review highlights areas for future research. Clinicians should interpret these findings as an overview of current understanding, not as a guide for practice.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Influenza A virus (IAV) continues to pose a substantial challenge to global health, not merely through primary viral pneumonia but largely due to lethal secondary bacterial complications. Pathogens such as Streptococcus pneumoniae, Staphylococcus aureus, and Haemophilus influenzae capitalize on the physiological “storm” induced by IAV, leading to significantly exacerbated morbidity. This review provides a comprehensive synthesis of the multifaceted mechanisms that dismantle host antibacterial defenses. Beyond the classical understanding of respiratory epithelial damage and the compensatory upregulation of bacterial adhesion receptors, we delve into the sophisticated dysregulation of innate immune signaling, specifically the collateral damage caused by interferon responses and impaired phagocytic function. Furthermore, we examine the complex roles of direct virus–bacterium synergism and the disruption of the respiratory microbiome (dysbiosis). By integrating these established paradigms, we extend the discussion to the rising clinical concern of nosocomial and multidrug-resistant (MDR) infections in critically ill patients. We conclude by identifying critical knowledge gaps and emphasizing the need for targeted strategies to mitigate the host vulnerabilities that permit opportunistic MDR colonization in the wake of viral insult.